Abstract
Cancer continues to pose a formidable challenge in global health due to its incidence and increasing resistance to conventional therapies. A key factor driving this resistance is tumor hypoxia, characterized by reduced oxygen levels within cancer cells. This hypoxic environment triggers a variety of adaptive mechanisms, significantly compromising the efficacy of cancer treatments. Notably, hypoxia promotes metastasis and reshapes the tumor microenvironment (TME), thereby aggravating treatment resistance. Central to this process are hypoxia-inducible factors (HIFs), which mediate cellular adaptations such as metabolic shifts and enhanced survival pathways. These adaptations render therapies like chemotherapy, radiotherapy, and photodynamic therapy (PDT) less effective. Additionally, hypoxia-induced vascular irregularities further impede drug delivery, amplifying the therapeutic challenge. This review provides a comprehensive examination of the roles of hypoxia in cancer, its contributions to drug resistance, and its interplay with apoptosis and autophagy. By evaluating novel mechanistic and translational approaches to target hypoxia, this study highlights the potential to improve therapeutic outcomes and offers insights into overcoming treatment resistance in cancer.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call